Study S002189

A Phase IIb, Randomized, Double-blind, Placebo-controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults With Type 2 Diabetes Mellitus.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06579105
Acronym: SOLSTICE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 406
Start: 2024-10-08
Primary completion: 2025-12-19
Lead sponsor: AstraZeneca
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Placebo (placebo matching AZD5004 film-coated tablet); DRUG:AZD5004; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2024-512562-34-00

Registered primary outcomes

Change in HbA1c [Baseline to Week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010921	Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial. Aroda VR, Lancet (London, England)	2026	Randomized trial	PMID 42259343 DOI	cites ClinicalTrials.gov:NCT06579105; cites CTIS:2024-512562-34-00; registry reference DERIVED:42259343